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Amyotrophic lateral sclerosis (ALS) is a chronic neuromuscular disorder, clinically 
characterized by muscle wasting, weakness and spasticity reflecting a progressive 
degeneration of upper and lower motor neurons. To date any treatments hardly prolong 
survival in ALS patients of some extent. Development of more effective neuroprotective 
therapies is impeded by lack of understanding of the mechanisms of neuronal death and 
how the disease propagates. Mesenchymal stem cells (MSC), a subset of adult stem cells 
derived from the bone marrow stroma, have generated much enthusiasm as possible cell 
source for tissue repair including the nervous system. Recent studies have shown different 
MSC roles as to modulate immune responses and to exert an anti-apoptotic effect on 
different cells including neurons. In addition, MSC can migrate into the central nervous 
system when i.v. injected. We studied here the effects of MSC administration in mice 
expressing mutant human super oxide dismutase (SOD1) with a G93A substitution 
[SOD1(+)/G93A(+)], a transgenic animal model of ALS. Mesenchymal cells (106 
cells/animal, i.v.) were injected at day 90, well after the onset of the first disease 
symptoms, that can be recorded at about day 60. Saline injected SOD1(+)/G93A(+) were 
used as controls. Control mice survived about 120 days while the MSC-treated mice 
exhibited a statistically significant prolonged survival time compared to saline injected 
controls. Such effect was associated with a significant amelioration in the performance of 
behavioral motor tests in the MSC-treated animals. Studying neurotransmitter release, we 
have found that glutamate exocytosis is enhanced in the spinal cord of SOD1(+)-G93A(+) 
mice, respect to controls. Interestingly, MSC treatment almost abolished this extra-release 
of the excitatory amino acid. Upon i.v. injection, a few luciferase-labeled MSCs were 
detected inside the mice spinal cord. Amelioration of some histological parameters was 
observed irrespective neural trans-differentiation. We can conclude that the treatment with 
MSC may be considered as an appealing therapeutic opportunity for ALS although the 
effect does not seem to rely on tissue repair.  
